Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoSil MedicalASX:OSL -10.34%46 Equity-to-Asset is 0.54 as of Dec. 2025, which is 37% below its 10-year median of 0.86. GuruFocus rates ASX:OSL with a GF Score™ of 46/100 and a GF Value™ of A$2.91 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 853 Medical Devices & Instruments companies, OncoSil Medical ranks worse than 62.95% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. OncoSil Medical's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$3.84 Mil. OncoSil Medical's Total Assets for the quarter that ended in Dec. 2025 was A$7.13 Mil.
Therefore, OncoSil Medical's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.54.
The historical rank and industry rank for OncoSil Medical's Equity-to-Asset or its related term are showing as below:
ASX:OSL'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.43 Med: 0.86 Max: 0.98
Current: 0.54
During the past 13 years, the highest Equity to Asset Ratio of OncoSil Medical was 0.98. The lowest was 0.43. And the median was 0.86.
ASX:OSL's Equity-to-Asset is ranked worse than 62.95% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs ASX:OSL: 0.54
OncoSil Medical (ASX:OSL) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
OncoSil Medical Equity-to-Asset Related Terms
OncoSil Medical Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for OncoSil Medical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:OSL vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, OncoSil Medical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoSil Medical Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where OncoSil Medical's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
OncoSil Medical's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoSil Medical (ASX:OSL) has a Equity-to-Asset of 0.54 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on OncoSil Medical and its competitors. This is 37% below median its historical median of 0.86. Over the past decade, OncoSil Medical's Equity-to-Asset has ranged from 0.43 to 0.98. According to the industry distribution chart, OncoSil Medical ranks #537 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 63%.
Is OncoSil Medical's Equity-to-Asset too high?
OncoSil Medical's current Equity-to-Asset of 0.54 is 37% below median its 10-year median of 0.86. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 0.98. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. OncoSil Medical's value of 0.54 is 16.9% below this industry median. Based on the distribution chart, OncoSil Medical ranks #537 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, OncoSil Medical has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OncoSil Medical ranks #537 out of 853 companies for Equity-to-Asset. This places OncoSil Medical in the lower half of its industry. The industry median Equity-to-Asset is 0.65. OncoSil Medical's value of 0.54 is 16.9% below this benchmark. Historically, OncoSil Medical's own Equity-to-Asset has ranged from 0.43 to 0.98 over the past decade. While the company's 10-year median is 0.86 vs. the industry median of 0.65, OncoSil Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoSil Medical's current Equity-to-Asset of 0.54 is 16.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on OncoSil Medical and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoSil Medical's current Equity-to-Asset is 0.54, which is 37% below median its own 10-year median of 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.91, compared to a current price of A$1.30 — trading 55.3% below its estimated fair value. The current Equity-to-Asset is 0.54, which is 37% below median its 10-year median of 0.86 and 16.9% below the Medical Devices & Instruments industry median of 0.65. OncoSil Medical's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current Equity-to-Asset is 0.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoSil Medical (ASX:OSL) Overvalued in 2026?
Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued.
The current stock price of A$1.30 is trading 55.3% below its estimated GF Value™ of A$2.91.
GuruFocus considers OncoSil Medical to be Possible Value Trap.
Key valuation signals for ASX:OSL:
Equity-to-Asset: 0.54 (37% below median its 10-year median of 0.86)
GF Value™: A$2.91 vs. price of A$1.30 (55.3% below fair value)
Industry Position: 16.9% below the Medical Devices & Instruments median (#537 of 853)
No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
46GF Score
Get the complete analysis for ASX:OSL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSL has been successfully added to your 
